Based on these observations, we conclude that many seemingly marginal health problems can concur in creating an individual fragility in the antioxidant defenses, which could be aggravated by the viral infection and could lead to the severe outcome of COVID-19
Key finding: AOD-9604 failed to produce statistically significant weight loss compared to placebo in a clinical trial
Quick Facts TypePeptide Blend (BPC-157 + TB-500) CategoryRecovery / Tissue Repair AdministrationSubcutaneous injection FrequencyDaily (loading) / 3x weekly (maintenance) Typical Dose250500 mcg of each per dose Cycle Length48 weeks Available Sizes5 mg/5 mg (10 mg total) vials Stability21 days after reconstitution Overview What is the BPC-157 / TB-500 Blend
This typically manifests as a queasy feeling rather than actual vomiting
Handling: Wear appropriate personal protective equipment (PPE)
Wang C, Su B, Lu S, Han S, Jiang H, Li Z, et al